• Anteris Technologies Global Corp. posted a net loss of USD 22.9 million, widening 4% year over year.
• Net sales slipped 11% to USD 494,000, while operating loss widened 10% to USD 24 million.
• Loss per share narrowed to USD 0.28 from USD 0.61, while research and development expense rose 6% to USD 17.5 million.
• Cash, cash equivalents and restricted cash jumped to USD 283.2 million from USD 12.6 million at Dec. 31, 2025, following USD 308.3 million of share-issuance proceeds net of underwriting fees.
• Recruitment continued for DurAVR THV PARADIGM Trial, with U.S. Medicare reimbursement eligibility secured in April 2026 and first U.S. patients enrolled and treated in May 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-020806), on May 12, 2026, and is solely responsible for the information contained therein.